PMEF
RCUS icon

Point72 Middle East FZE’s Arcus Biosciences RCUS Stock Holding History

Point72 Middle East FZE’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,080
Closed -$360K – 1815
2023
Q3 		$360K Buy
+20,080
New +$403K 0.01% 893
2023
Q1 		– Sell
-2,781
Closed -$57.5K – 2098
2022
Q4 		$57.5K Buy
+2,781
New +$76.5K ﹤0.01% 1415

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Middle East FZE's RCUS Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 20,080 shares — an estimated $360K sold.

Point72 Middle East FZE first reported a position in RCUS in Q4 2022 and held it in 2 quarters. The position peaked at $360K in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 20,080 Arcus Biosciences shares in Q4 2023, an estimated $360K.
  • Point72 Middle East FZE first reported a position in Arcus Biosciences in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Arcus Biosciences position peaked at $360K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.